Rheumatoid Arthritis

Foot and Ankle Clinics

Volumn 12, Issue 3, 2007, Pages 525-537

  Lorenzo, Marlyn ^a  

^a MERCY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; NONSTEROID ANTIINFLAMMATORY AGENT;

HUMAN; METHODOLOGY; PERIOPERATIVE PERIOD; REVIEW; RHEUMATOID ARTHRITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; HUMANS; PERIOPERATIVE CARE;

EID: 34548262754     PISSN: 10837515     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fcl.2007.04.004     Document Type: Review

References (60)

1. Harris Jr. E.D., Budd R.C., Firestein G.S., et al. Kelley's textbook of rheumatology. 7th edition (2005), Elsevier Saunders p. 996
2. Raza K., Breese M., Nightingale P., et al. Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. J Rheumatol 32 (2005) 231-238
3. Lee D.M., and Schur P.H. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 62 (2003) 870
4. Zeng X., Ai M., Tian X., et al. Diagnostic value of anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis. J Rheumatol 30 (2003) 1451
5. Van Gaalen F.A., Linn-Rasker S.P., van Venrooij W.J., et al. Autoantibodies to cyclic citrullinated peptides predicts progression to rheumatoid arthritis in patients with undifferentiated arthritis. Arthritis Rheum 50 (2004) 709
6. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 Revised Criteria for the Classification of Rheumatoid Arthritis. Arthritis Rheum 31 (1988) 315-324
7. Prescribing information, Sulfasalazine delayed release tablets, USP (Azulfidine EN-tabs ®). Pharmacia & Upjohn Company, Division of Pfizer Inc. New York, New York; 2006.
8. Kremer J.M., Alarcón G.S., Lightfoot R.W., et al. Methotrexate for rheumatoid arthritis: Suggested guidelines for monitoring liver toxicity. Arthritis Rheum 3 (1994) 316
9. Prescribing information, Methotrexate sodium tablets (Rheumatrex ®). Heumann Pharma Gmblt, for Stada Pharmaceuticals Inc, Cranbury, New Jersey; 2003.
10. O'Dell J.R., Leff R., Paulsen G., et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46 (2002) 1164
11. O'Dell J.R., Haire C.E., Erikson N., et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 334 (1996) 1287
12. Montesinos M.C., Desai A., Delano D., et al. Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum 48 (2003) 240
13. Cronstein B.N., Naime D., and Ostad E. The anti-inflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest (1993) 2675-2682
14. Prescribing information. Etanercept (Enbrel®) Immunex Corporation, Thousand Oaks, California; 2006.
15. Prescribing information. Infliximab (Remicade®) Centocor Inc.; 2006.
16. Prescribing information. Adalimumab (Humira®) Abbott Laboratories, North Chicago, Illinois; 2006.
17. Moreland L.W., Baumgatner S.W., Schiff M.H., et al. Treatment of rheumatoid arthritis with a recombinant tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337 (1997) 141
18. Moreland L.W., Schiff M.H., Baumgartner S.W., et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130 (1999) 478
19. Weinblatt M.H., Kremer J.M., Bankhurst A.D., et al. A trial of etanercept, a TNF receptor: Fc fusion protein in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340 (1999) 253
20. Moreland L.W., Cohen S.B., Baumgartner S.W., et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 28 (2001) 1238
21. Bathon J.M., Martin R.W., Fleischmann R.M., et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343 (2000) 1586
22. Petersen K., Leff R., Paulsen G., et al. Etanercept in combination with sulfasalazine (SSA), hydroxychloroquine (HCQ), or gold in the treatment of rheumatoid arthritis (RA). [abstract]. Arthritis Rheum 48 (2003) S324
23. Maini R., St. Clair E.W., Breedveld F., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 354 (1999) 1932
24. Lipsky P.E., van der Heijde D.M., St Clair E.W., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343 (2000) 1594
25. Maini R.N., Breedveld F.C., Kalden J.R., et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 50 (2004) 1051
26. Breedveld F.C., Emery P., Keystone E., et al. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 63 (2004) 149
27. St Clair E.W., Wagner C.L., Fasanmade A.A., et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46 (2002) 1451
28. Westhovens R., Yocum D., Han J., et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 54 (2006) 1075
29. St Clair E.W., van der Heijde D.M., Smolen J.S., et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50 (2004) 3432
30. Weinblatt M.E., Keystone E.C., Furst D.E., et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48 (2003) 35
31. van de Putte L.B., Atkins C., Malaise M., et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 63 (2004) 508
32. Keystone E.C., Kavanaugh A.F., Sharp J.T., et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50 (2004) 1400
33. Breedveld F.C., Weisman M.H., Kavanaugh A.F., et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54 (2006) 26
34. Prescribing information. Abatacept (Orencia®) Bristol-Myers Squibb Company, Princeton, New Jersey; 2007.
35. Kremer J.M., Westhovens R., Leon M.M.D., et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349 (2003) 1907-1915
36. Kremer J.M., Dougados M., Emery P., et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52 (2005) 2263
37. Westhovens R., Cole J.C., Li T., et al. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. Rheumatology (Oxford) 45 (2006) 1238-1246
38. Edwards J.C., Szczepanski L., Szechinski J., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350 (2004) 2572
39. Graham D.J., Campen D., Hui R., et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365 (2005) 475
40. Levesque L.E., Brophy J.M., and Zhang B. Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors. CMAJ 174 (2006) 1563
41. Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 284 (2000) 1247
42. White W.B., Faich G., Borer J.S., et al. Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am J Cardiol 92 (2003) 411
43. Singh G., Fort J.G., Goldstein J.L., et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 119 (2006) 255
44. Andersohn F., Schade R., Suissa S., et al. Cyclooxygenase-2 selective nonsteroidal antiinflammatory drugs and the risk of ischemic stroke: a nested case-control study. Stroke 37 (2006) 1725
45. Bertagnolli M.M., Eagle C.J., Zauber A.G., et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355 (2006) 873
46. Arber N., Eagle C.J., Spicak J., et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355 (2006) 885
47. Busti A.J., Hooper J.S., Amaya C.J., et al. Effects of perioperative antiinflammatory and immunomodulating therapy on surgical wound healing. Pharmacotherapy 25 11 (2005) 1566-1591
48. Jain A., Maini R., and Nanchahal J. Disease modifying treatment and elective surgery in rheumatoid arthritis: the need for more data. Ann Rheum Dis 63 (2004) 602
49. Bridges Jr. S.L., Lopez-Mendez A., Han K.H., et al. Should methotrexate be discontinued before elective orthopedic surgery in patients with rheumatoid arthritis?. J Rheumatol 18 (1991) 984
50. Carpenter M.T., West S.G., Vogelgesang S.A., et al. Postoperative joint infections in rheumatoid arthritis patients on methotrexate therapy. Orthopedics 19 (1996) 207
51. Escalante A., and Beardmore T.D. Risk factors for early wound complications after orthopedic surgery for rheumatoid arthritis. J Rheumatol 22 (1995) 1844
52. Grennan D.M., Gray J., Loudon J., et al. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis 60 (2001) 214-217
53. Jain A., Witbreuk M., Ball C., et al. Influence of steroids and methotrexate on wound complications after elective rheumatoid hand and wrist surgery. J Hand Surg [Am] 27 (2002) 449-455
54. Kasdan M.L., and June L. Postoperative results of rheumatoid arthritis patients on methotrexate at the time of reconstructive surgery of the hand. Orthopedics 16 (1993) 1233
55. Perhala R.S., Wilke W.S., Clough J.D., et al. Local infectious complications following large joint replacement in rheumatoid arthritis patients treated with methotrexate versus those not treated with methotrexate. Arthritis Rheum 34 (1991) 146
56. Sany J., Anaya J.M., Canovas F., et al. Influence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis. J Rheumatol 20 (1993) 1129-1132
57. Bibbo C., and Goldberg J.W. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int 25 (2004) 331-335
58. Talwalkar S.C., Grennan D.M., Gray J., et al. Tumour necrosis factor alpha antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery. Ann Rheum Dis 64 (2005) 650
59. Giles J.T., Bartlett S.J., Gelber A.C., et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum 55 (2006) 333
60. Fuerst M., Mohl H., Baumgartel K., et al. Leflunomide increased the risk of early healing complications in patients with rheumatoid arthritis undergoing elective orthopedic surgery. Rheumatol Int 26 12 (2006) 1138-1142